Concert Pharmaceuticals Inc. (CNCE)

11.21
NASDAQ : Health Technology
Prev Close 10.98
Day Low/High 10.87 / 11.35
52 Wk Low/High 9.21 / 20.21
Avg Volume 311.10K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 261.28M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEY, ALSK, CNCE, CYRN, IBM, KFS, LUK, MGNX, MOCO, TSC, TTI Downgrades: ABT, BIOS, FARM, HGR, ING, IRT, MAG, PHG, PRO Initiations: AMBR, CORI, STKS Read on to get TheStreet Quant Ratings' detailed report:

Flamel Jumps After Competitors Scrap Narcolepsy Drug Development

Flamel Jumps After Competitors Scrap Narcolepsy Drug Development

The shares of Flamel Technologies are rallying after two other companies, Jazz Pharmaceuticals and Concert Pharmaceuticals, decided not to continue development of their JZP-386 drug at this time.

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2015.

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals To Report First Quarter 2015 Financial Results On May 8, 2015

Concert Pharmaceuticals To Report First Quarter 2015 Financial Results On May 8, 2015

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2015 financial results on Friday, May 8, 2015 before the U.

Concert Pharmaceuticals To Present At 14th Annual Needham Healthcare Conference

Concert Pharmaceuticals To Present At 14th Annual Needham Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 14 th Annual Needham Healthcare Conference, Tuesday, April 14, 2015 at 4:20 p.

Concert Pharmaceuticals Announces Pricing Of Public Offering

Concert Pharmaceuticals Announces Pricing Of Public Offering

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $15.

Concert Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Concert Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has commenced an underwritten public offering of its common stock.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, FF, HTBI Downgrades: ANN, CLGX, FTD, GSVC, NGS, QSII, RNET, TSU Initiations: AMDA, CNCE, IBP Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that is has initiated its Phase 1 clinical program for deuterium-modified ivacaftor, a novel, potentially disease-modifying treatment for cystic fibrosis.

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2014 and provided an update on its product pipeline and corporate activities.

Concert Pharmaceuticals To Present At Three Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Three Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The 35 th Annual Cowen and Company Healthcare...

Concert Pharmaceuticals To Report Full Year 2014 Results On February 27, 2015

Concert Pharmaceuticals To Report Full Year 2014 Results On February 27, 2015

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2014 on Friday, February 27, 2015 before the US financial markets open.

Concert Pharmaceuticals Announces Appointment Of James V. Cassella As Chief Development Officer

Concert Pharmaceuticals Announces Appointment Of James V. Cassella As Chief Development Officer

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V.

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 22, 2014.

Concert Pharmaceuticals Becomes Oversold (CNCE)

Concert Pharmaceuticals Becomes Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G.

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Update On CTP-354 Program

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Update On CTP-354 Program

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2014 and provided an update on its pipeline and CTP-354.

Concert Pharmaceuticals To Present At Stifel 2014 Healthcare Conference On November 18, 2014

Concert Pharmaceuticals To Present At Stifel 2014 Healthcare Conference On November 18, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Stifel 2014 Healthcare Conference, November 18, 2014 at 1:50 p.

Concert Pharmaceuticals To Report Third Quarter 2014 Results On November 12, 2014

Concert Pharmaceuticals To Report Third Quarter 2014 Results On November 12, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2014 financial results on Wednesday, November 12, 2014 before the financial markets open.

Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-354, Lead Candidate For The Treatment Of Spasticity

Concert Pharmaceuticals Presents Positive Data From Multiple Dose Phase 1 Clinical Trial Of CTP-354, Lead Candidate For The Treatment Of Spasticity

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity.

Concert Pharmaceuticals Announces Initiation Of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

Concert Pharmaceuticals Announces Initiation Of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with...

4 Under-$10 Biotech Stocks in Breakout Territory

4 Under-$10 Biotech Stocks in Breakout Territory

These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.

Concert Pharmaceuticals Achieves $2 Million Milestone For AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Achieves $2 Million Milestone For AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc.

Concert Pharmaceuticals To Present At Robert W. Baird 2014 Healthcare Conference On September 4, 2014

Concert Pharmaceuticals To Present At Robert W. Baird 2014 Healthcare Conference On September 4, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present an overview at the Robert W.

4 Stocks Under $10 Making Big Moves

4 Stocks Under $10 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2014.

Concert Pharmaceuticals To Report Second Quarter 2014 Results On August 12, 2014

Concert Pharmaceuticals To Report Second Quarter 2014 Results On August 12, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2014 financial results on Tuesday, August 12, 2014 before the financial markets open.

Http://www.jazzpharmaceuticals.com/

Http://www.jazzpharmaceuticals.com/

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc.

TheStreet Quant Rating: D (Sell)